MODELLING THE LONG-TERM SURVIVAL OF PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS) DEL (5Q) TREATED WITH LENALIDOMIDE

被引：0
|
作者：
Benettaib, B. [1 ]
Lee, D. [2 ]
Dhanasiri, S. [3 ]
Brereton, N. [2 ]
机构：
[1] Sarl, Celgene Int, Geneva, Switzerland
[2] BresMed, Sheffield, S Yorkshire, England
[3] Celgene Ltd, Uxbridge, Middx, England
来源：
HAEMATOLOGICA | 2013年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P740
引用
收藏
页码：310 / 310
页数：1
相关论文
共 50 条
  • [1] Conditional Survival in Patients with Del(5q) Myelodysplastic Syndromes Treated with Lenalidomide
    Gerds, Aaron T.
    List, Alan F.
    Giagounidis, Aristoteles
    Hellstrom-Lindberg, Eva
    Li, Jack Shiansong
    Swern, Arlene S.
    Sugrue, Mary M.
    Fenaux, Pierre
    Sekeres, Mikkael A.
    BLOOD, 2015, 126 (23)
  • [2] MYELODYSPLASTIC SYNDROME WITH DEL(5Q) AND LENALIDOMIDE
    Gritsaev, S. V.
    Martinkevitch, I. S.
    Petrova, E. V.
    GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2013, 58 (02): : 3 - 10
  • [3] Long-term transfusion independence in del(5q) MDS patients who discontinue lenalidomide
    Giagounidis, A. A. N.
    Kulasekararaj, A.
    Germing, U.
    Radkowski, R.
    Haase, S.
    Petersen, P.
    Goehring, G.
    Buesche, G.
    Aul, C.
    Mufti, G. J.
    Platzbecker, U.
    LEUKEMIA, 2012, 26 (04) : 855 - 858
  • [4] Long-term transfusion independence in del(5q) MDS patients who discontinue lenalidomide
    A A N Giagounidis
    A Kulasekararaj
    U Germing
    R Radkowski
    S Haase
    P Petersen
    G Göhring
    G Büsche
    C Aul
    G J Mufti
    U Platzbecker
    Leukemia, 2012, 26 : 855 - 858
  • [5] DEFINING LIKELIHOOD OF FUTURE RESPONSE IN PATIENTS WITH DEL(5Q) MYELODYSPLASTIC SYNDROMES (MDS) TREATED WITH LENALIDOMIDE
    Gerds, A. T.
    List, A. F.
    Giagounidis, A.
    Hellstrom-Lindberg, E.
    Li, J. Shiansong
    Swern, A. S.
    Sugrue, M. M.
    Fenaux, P.
    Sekeres, M. A.
    LEUKEMIA RESEARCH, 2015, 39 : S109 - S109
  • [6] Mechanisms of Resistance to Lenalidomide in Del(5q) Myelodysplastic Syndrome Patients
    Martinez-Hoyer, Sergio
    Docking, Rod
    Chan, Simon
    Jadersten, Martin
    Parker, Jeremy
    Karsan, Aly
    BLOOD, 2015, 126 (23)
  • [7] Survival of Patients with Del(5q) Syndrome in the Lenalidomide Era
    Reagan, John L.
    Ollila, Thomas
    Dubielecka, Patrycja M.
    Olszewski, Adam J.
    BLOOD, 2016, 128 (22)
  • [8] Disease progression in del(5q) MDS patients treated with lenalidomide: analysis of risk factors and long-term outcome in 44 patients
    Giagounidis, A. A. N.
    Haase, S.
    Lohrbacher, V.
    Heinsch, M.
    Schuran, B.
    Aul, C.
    LEUKEMIA RESEARCH, 2007, 31 : S120 - S121
  • [9] Survival of patients with de novo myelodysplastic syndromes (MDS) and del(5q)
    Gritsaev, S.
    Martinkevitch, I.
    Petrova, E.
    Kostroma, I.
    Ivanova, M.
    Sergeev, A.
    Tiranova, S.
    Potichonova, N.
    LEUKEMIA RESEARCH, 2013, 37 : S88 - S88
  • [10] Long-term outcome of MDS with del 5q before the lenalidomide era. The GFM experience
    Kelaidi, C.
    Park, S.
    Tamburini, J.
    Sapena, R.
    Raffoux, E.
    Beyne-Rauzy, O.
    Coiteux, V.
    Aljassem, L.
    Prebet, T.
    Legros, L.
    Stamatoullas, A.
    Sanhes, L.
    Delarue, R.
    Dreyfus, F.
    Fenaux, P.
    LEUKEMIA RESEARCH, 2009, 33 : S124 - S124
12345